Transitioning from Heparin to Apixaban

General Principles

The American College of Cardiology recommends that apixaban should be started immediately when the next dose of heparin would be due, with no need for overlapping therapy, due to its rapid onset of action 1
Apixaban achieves therapeutic anticoagulation rapidly, with peak effect within 3-4 hours of administration, which is a key factor in its use for patients transitioning from heparin 1, 2
Direct oral anticoagulants like apixaban do not require extended overlap periods with heparin, unlike warfarin which requires 5-10 days of overlapping therapy 1

For patients transitioning from intravenous unfractionated heparin to apixaban, the heparin infusion should be discontinued and apixaban started immediately when the next dose of heparin would have been due, with no need for overlapping therapy due to the short half-life of UFH 1, 2
For patients transitioning from low molecular weight heparin to apixaban, the first dose of apixaban should be administered at the time the next scheduled dose of LMWH would be due, with no need for overlapping therapy 1

For venous thromboembolism treatment, apixaban should be started at 10 mg twice daily for 7 days, followed by 5 mg twice daily, as recommended by the American College of Cardiology 1, 3
For atrial fibrillation, standard dosing is 5 mg twice daily, or 2.5 mg twice daily in patients meeting dose reduction criteria, according to the American Heart Association 3

Apixaban has less renal clearance (25%) and generally doesn't require adjustment solely for mild to moderate renal impairment, unlike dabigatran which requires dose adjustments based on renal function 1, 3
If a patient is being transitioned for an upcoming procedure with high bleeding risk, apixaban should be discontinued 2-3 days before the procedure, as recommended by the American College of Cardiology 2, 4
For patients with normal renal function, holding apixaban for 24-48 hours is generally sufficient before a high bleeding risk procedure, according to the American College of Cardiology 5

Avoid unnecessary bridging with parenteral anticoagulants, as apixaban does not require bridging, according to the American College of Cardiology 1, 4
Avoid overlapping therapy with heparin and apixaban, as it increases bleeding risk without additional antithrombotic benefit, as recommended by the American Heart Association 1
Avoid delaying transition to apixaban, as prompt transition reduces hospitalization time and costs, according to the American College of Cardiology 1
Avoid incorrect dosing, and ensure the correct initial dosing regimen is used based on the indication, as recommended by the American College of Cardiology 1, 3